AVITA MEDICAL WKN: A0Q40S ISIN: AU000000AVH4 Kürzel: AVMXF Forum: Aktien Thema: Hauptdiskussion

Irgendwie ist die Aktie den 2. Tag hintereinander ab 15.30 nicht handelbar....seltsam

https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-reports-first-quarter-2025-financial-results

https://www.stocktitan.net/news/RCEL/avita-medical-announces-exclusive-manufacturing-and-distribution-wsvryztodl3h.html

https://www.stocktitan.net/news/RCEL/avita-medical-reports-fourth-quarter-and-full-year-2024-financial-2bnye0ed3uc8.html

https://www.globenewswire.com/news-release/2024/12/23/3001481/0/en/AVITA-Medical-Announces-FDA-Approval-of-RECELL-GO-mini-Optimizing-Treatment-for-Smaller-Wounds.html

https://finance.yahoo.com/news/avita-medical-announces-exclusive-distribution-210300969.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAABCmTeUi1PfBK9fGI6U8ogG87y1tWw_xQR3CE_x6OlDFqkpuEhzZMbtbvsfPY_02zAvvOovtIfACFvDOO9ZakCrlnCWjJIK71uo1FtPqXwN2XDUNGjgv13D9Al5ATc9DB55_bbHWTigC9_C6MBJ9vKKATvfeKf7NUpa_l9CY-n-6

https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-reports-third-quarter-financial-results

Noch jemand hier ?

https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-reports-second-quarter-financial-results-0

https://www.globenewswire.com/news-release/2024/05/30/2890849/0/en/AVITA-Medical-Announces-FDA-Approval-of-RECELL-GO.html

https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-reports-first-quarter-financial-results

https://www.xm.com/research/markets/allNews/reuters/avita-medicals-asx-shares-drop-to-3month-low-on-revenue-forecast-downgrade-53810377

https://announcements.4dsmemory.com/announcements/6226600

https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-reports-fourth-quarter-and-full-year-2023

Cantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS https://seekingalpha.com/news/4056668-cantor-picks-rcel-as-best-2024-medtech-idea-bullish-on-pacb-axgn-cers ... The investment bank said it chose skin restoration products provider AVITA based on its “top-tier” growth rate of around 64% year-over-year and gross margins of approximately 85%. “We believe RECL should trade at a premium to peers given the company’s superior growth profile and best-in-class gross margins,” Cantor analysts wrote in a recent note. Cantor pointed out that AVITA’s recent guidance excluded revenue for the expected launch of PermeaDerm under the company’s distribution agreement with Stedical Scientific. It added that it was increasing its 2024 commercial revenue estimates for the company to $82.9M, which it believes is still “conservative” as it doesn’t include revenue from the launch. ...

https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-announces-exclusive-distribution-agreement